ABSTRACT
Peripheral insulin resistance is associated with decreasing adiponectin and increasing leptin plasma levels, and also with cognitive decline. The effects of adipokines on brain function have been published from both animal and human studies. In particular, the influence of leptin and adiponectin on the development of Alzheimer's disease (AD) has been extensively investigated. However, the association between adipsin and AD is as yet unknown. In 37 patients with AD and 65 controls that followed the same study protocol, we tested whether adiponectin, leptin, and adipsin could be used as biomarkers in the early stages of AD. In contrast with conclusions of cognition studies in insulin resistant states, our study found a correlation of impaired neuropsychological performance with increasing adiponectin and decreasing leptin in AD patients. Nevertheless, no significant differences between patients and controls were found. AD women had significantly increased adipsin compared to controls, and there was a positive correlation of adipsin with age and disease duration. Although adipokines do not appear to be suitable biomarkers for early AD diagnosis, they certainly play a role in the pathogenesis of AD. Further studies will be needed to explain the cause of the adipokine "breaking point" that leads to the pathogenesis of overt AD.
Subject(s)
Adiponectin/blood , Alzheimer Disease/pathology , Biomarkers/blood , Complement Factor D/analysis , Leptin/blood , Alzheimer Disease/blood , Case-Control Studies , Female , Humans , Male , Middle AgedABSTRACT
Alzheimer's disease (AD) is the most common type of dementia, with a prevalence that is rising every year. AD is associated with type 2 diabetes mellitus (T2DM) and insulin resistance, and is therefore sometimes called "type 3 diabetes mellitus". The aim of this study was to examine whether the variants of some candidate genes involved in the development of AD, namely BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), and PICALM (rs3851179), are related to several disorders of glucose metabolism-gestational diabetes (GDM), T2DM and impaired glucose tolerance (IGT). Our study included 550 women with former GDM and 717 control women, 392 patients with T2DM and 180 non-diabetic controls, and 117 patients with IGT and 630 controls with normal glucose tolerance. Genotyping analysis was performed using specially-designed TaqMan assays. No significant associations of the genetic variants rs744373 in BIN1, rs11136000 in CLU, or rs3818361 in CR1 were found with GDM, T2DM or IGT, but rs3851179 in PICALM was associated with an increased risk of GDM. The frequency of the AD risk-associated C allele was significantly higher in the GDM group compared to controls: OR 1.21; 95% CI (1.03-1.44). This finding was not apparent in T2DM and IGT; conversely, the C allele of the PICALM SNP was protective for IGT: OR 0.67; 95% CI (0.51-0.89). This study demonstrates an association between PICALM rs3851179 and GDM as well as IGT. However, elucidation of the possible role of this gene in the pathogenesis of GDM requires further independent studies.
Subject(s)
Alzheimer Disease/genetics , Diabetes, Gestational/genetics , Glucose Intolerance/genetics , Monomeric Clathrin Assembly Proteins/genetics , Adaptor Proteins, Signal Transducing/blood , Adaptor Proteins, Signal Transducing/genetics , Adult , Aged , Alleles , Alzheimer Disease/complications , Clusterin/blood , Clusterin/genetics , Diabetes Mellitus, Type 2/genetics , Diabetes, Gestational/metabolism , Female , Gene Frequency , Genetic Association Studies/methods , Genetic Predisposition to Disease , Genetic Variation , Glucose Intolerance/metabolism , Humans , Middle Aged , Monomeric Clathrin Assembly Proteins/blood , Nuclear Proteins/blood , Nuclear Proteins/genetics , Odds Ratio , Polymorphism, Single Nucleotide/genetics , Pregnancy , Receptors, Complement 3b/blood , Receptors, Complement 3b/genetics , Risk Factors , Tumor Suppressor Proteins/blood , Tumor Suppressor Proteins/genetics , White People/geneticsABSTRACT
Steroids are important components in the pathophysiology of Alzheimer's disease (AD). Although their role has been studied, the corresponding metabolomic data is limited. In the present study we evaluate the role of steroid sulfotransferase SULT2A1 in the pathophysiology of AD on the basis of circulating steroids (measured by GC-MS), in which the sulfation catalyzed by SULT2A1 dominates over glucuronidation (pregnenolone/sulfate, DHEA/sulfate, androstenediol/sulfate and 5alpha-reduced pregnane and androstane catabolites). To estimate a general trend of SUL2A1 activity in AD patients we compared the ratios of steroid conjugates to their unconjugated counterparts (C/U) in controls (11 men and 22 women) and AD patients (18 men and 16 women) for individual circulating steroids after adjustment for age and BMI using ANCOVA model including the factors AD status and gender. Decreased C/U ratio for the C19 steroids demonstrate an association between attenuated sulfation of C19 steroids in adrenal zona reticularis and the pathophysiology of AD.
Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/diagnosis , Sulfotransferases/blood , Aged , Biomarkers/blood , Enzyme Activation/physiology , Female , Humans , Male , Zona Reticularis/metabolismABSTRACT
Human prion diseases are a group of very rare diseases with a unique pathogenesis and, due to an inauspicious prognosis and unavailability of therapy, with fatal consequences. The etiopathogenetic background is the presence of pathologically misfolded prion protein, highly resistant to denaturation, the aggregation and presence of which in the brain tissue causes irreversible neuronal damage. The most frequent prion disease in humans is Creutzfeldt-Jakob disease (CJD) which occurs in sporadic, hereditary/familial, or acquired/infectious/iatrogenic forms. A new form of CJD, variant CJD, is considered to be linked to dietary exposure to beef products from cattle infected with bovine spongiform encephalopathy (BSE) and to infection via blood transfusion. The clinical picture of these diseases is characterized by a rapidly progressing dementia, cerebellar and extrapyramidal symptoms, and rather specific MRI, EEG, and CSF findings. Clinically, the diagnosis is described as possible or probable prion disease and needs to be confirmed by neuropathological or immunological investigation of the brain tissue. Epidemiological data from the Czech Republic spanning the last decade are presented.
Subject(s)
Creutzfeldt-Jakob Syndrome/epidemiology , Animals , Cattle , Cattle Diseases/epidemiology , Creutzfeldt-Jakob Syndrome/etiology , Creutzfeldt-Jakob Syndrome/transmission , Czech Republic/epidemiology , Encephalopathy, Bovine Spongiform/epidemiology , Encephalopathy, Bovine Spongiform/transmission , Humans , Transfusion ReactionABSTRACT
BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.
Subject(s)
Dementia , Alzheimer Disease/diagnosis , Alzheimer Disease/therapy , Dementia/diagnosis , Dementia/therapy , Dementia, Vascular/diagnosis , Dementia, Vascular/therapy , Frontotemporal Lobar Degeneration/diagnosis , Frontotemporal Lobar Degeneration/therapy , Humans , Huntington Disease/diagnosis , Huntington Disease/therapy , Hydrocephalus, Normal Pressure/diagnosis , Hydrocephalus, Normal Pressure/therapy , Lewy Body Disease/diagnosis , Lewy Body Disease/therapy , Limbic Encephalitis/diagnosis , Limbic Encephalitis/therapy , Parkinson Disease/diagnosis , Parkinson Disease/therapy , Primary Progressive Nonfluent Aphasia/diagnosis , Primary Progressive Nonfluent Aphasia/therapy , Prion Diseases/diagnosis , Prion Diseases/therapy , Supranuclear Palsy, Progressive/diagnosis , Supranuclear Palsy, Progressive/therapyABSTRACT
Neurodegenerative disorders are progressive diseases characterized by loss of specific neuronal populations followed by a clinical picture of a different neurodegenerative entity. Current classification of these diseases respects the names of the main pathophysiological processes involved in the groups of disorders. This is the reason why key proteins which represent neuropathological and biochemical hallmarks of diseases are found in their names. Neuropathological diagnosis is a synthesis of neurohistological changes in the brain and spinal cord and identification of pathological proteinaceous aggregates in neurons and/or glial cells. These inclusions are predominant diagnostic micromorphological and biochemical markers of disease. In the text, there is a brief summary of current knowledge about pathophysiology of neurodegenerations and diagnostic criteria for the most frequent entities.
Subject(s)
Neurodegenerative Diseases/classification , Brain/pathology , Humans , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/pathologyABSTRACT
Whipples disease is a chronic multisystem inflammatory disease with predominantly gastrointestinal manifestations due to Tropheryma whipplei infection. Typical neurological abnormalities include dementia, eye movement abnormalities, hypothalamic dysfunction and oculomasticatory myorhythmias. The literature on peripheral neuropathy in Whipples disease is sparse and the involvement of peripheral nerves in Whipples disease has not been documented convincingly so far. We present a case of Whipples disease presenting by axonal peripheral neuropathy without gastrointestinal involvement. The diagnosis was confirmed by a sural nerve biopsy and consequent PCR of the sample. All clinical signs disappeared progressively during the antibiotic therapy. Two years after the T. whipplei infection, the patient developed dopa-sensitive Parkinson's disease, although these two events seem to be unrelated. This case illustrates the value of peripheral nerve biopsy in cases of axonal neuropathy of unexplained origin and extends the clinical spectrum of Whipples disease to a new modality.
Subject(s)
Peripheral Nervous System Diseases/pathology , Whipple Disease/complications , Humans , Male , Middle Aged , Peripheral Nerves/pathology , Peripheral Nervous System Diseases/etiologyABSTRACT
BACKGROUND: The aim of the study was to assess autoimmune involvement in amyotrophic lateral sclerosis (ALS). METHODS: We measured IgG antibodies against light (NFL) and medium (NFM) subunits of neurofilaments using ELISA in paired cerebrospinal fluid (CSF) and serum samples from 38 ALS patients and 20 controls. RESULTS: Serum levels of anti-NFL were higher in ALS patients than in controls (P < 0.005). Serum anti-NFL antibodies and intrathecal anti-NFM antibodies were related to patient disability (serum anti-NFL: P < 0.05; intrathecal anti-NFM: P < 0.05). Anti-NFL levels were significantly correlated with anti-NFM levels in ALS (P < 0.001) and the control group (P < 0.0001) in the CSF, but not in serum. Anti-NFL and anti-NFM antibodies significantly correlated between serum and CSF in the ALS group (anti-NFL: P < 0.0001; anti-NFM: P < 0.001) and in the control group (anti-NFL: P < 0.05; anti-NFM: P < 0.05). CONCLUSIONS: Autoimmune humoral response to neurocytoskeletal proteins is associated with ALS.
Subject(s)
Amyotrophic Lateral Sclerosis/immunology , Autoantibodies/blood , Autoantibodies/cerebrospinal fluid , Immunoglobulin G/blood , Immunoglobulin G/cerebrospinal fluid , Neurofilament Proteins/immunology , Aged , Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/cerebrospinal fluid , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Severity of Illness Index , Time FactorsABSTRACT
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disease affecting motor neurons and may be associated with impaired cognition. Reliable prognostic factors for ALS patients are still missing. METHODS: We prospectively included 67 patients, 42 women and 25 men, with clinically defined ALS. The disease severity was assessed and the patients underwent SPECT, lumbar puncture with determination of tau, hyperphosporylated tau (p-tau) and beta-amyloid and a detailed neuropsychological assessment using a standardized test battery. In patients who died, a detailed neuropathologic evaluation was performed. RESULTS: The mean survival duration was 26.8 months. The delay between the first signs and confirmation of the diagnosis was 12.75 months. Cognitive impairment did not have an impact on the evolution of the disease. There was no correlation between neuropsychological and SPECT findings. Higher age at onset, more pronounced handicap and elevated beta-amyloid in the CSF were associated with shorter survival times. In brain tissue from nine of the deceased patients with ALS and dementia, all showed signs of comorbidity, six had hallmarks of frontotemporal lobar degeneration (FTLD) and three showed Alzheimer disease pathology. Brain tissues form 11 deceased ALS patients who did not show signs of dementia, had only changes compatible with a diagnosis of motor neuron disease. CONCLUSION: In our prospective study, age, disease severity and CSF beta-amyloid levels taken together were a risk factor suggesting shorter survival times. Dementia is relatively frequent in ALS and may be a consequence of either FTLD or result from co-existing Alzheimer disease.
Subject(s)
Amyotrophic Lateral Sclerosis/diagnosis , Amyotrophic Lateral Sclerosis/mortality , Brain/pathology , Cognition Disorders/diagnosis , Cognition Disorders/mortality , Adult , Age of Onset , Aged , Alzheimer Disease/diagnosis , Alzheimer Disease/mortality , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/analysis , Amyloid beta-Peptides/cerebrospinal fluid , Amyotrophic Lateral Sclerosis/physiopathology , Autopsy , Biomarkers/analysis , Biomarkers/cerebrospinal fluid , Brain/diagnostic imaging , Brain/physiopathology , Cognition Disorders/physiopathology , Comorbidity , Disability Evaluation , Disease Progression , Female , Frontotemporal Dementia/diagnosis , Frontotemporal Dementia/mortality , Frontotemporal Dementia/physiopathology , Humans , Male , Middle Aged , Mortality , Neuropsychological Tests , Predictive Value of Tests , Prognosis , Prospective Studies , Severity of Illness Index , Spinal Puncture , Survival Rate , Tomography, Emission-Computed, Single-Photon , tau Proteins/analysis , tau Proteins/cerebrospinal fluidABSTRACT
Amyotrophic lateral sclerosis (ALS) may be accompanied by cognitive impairment; when present, it is mainly in the form of frontotemporal impairment. We report on two cases with clinically defined ALS that subsequently developed dementia. Neuropathological examination showed not only the typical neuropathological hallmarks characteristic of ALS but, surprisingly, also showed neurofibrillary tangles and neuritic plaques in sufficient numbers to fulfill the diagnostic criteria of definite Alzheimer's disease.
Subject(s)
Alzheimer Disease/complications , Amyotrophic Lateral Sclerosis/complications , Brain/pathology , Dementia/etiology , Spinal Cord/pathology , Aged , Alzheimer Disease/pathology , Amyotrophic Lateral Sclerosis/pathology , Amyotrophic Lateral Sclerosis/psychology , Anterior Horn Cells/pathology , Cranial Nerves/pathology , Dementia/pathology , Disease Progression , Dysarthria/etiology , Female , Humans , Male , Memory Disorders/etiology , Middle Aged , Neurofibrillary Tangles , Paralysis/etiology , Plaque, AmyloidABSTRACT
Multiple system atrophy (MSA) is a neurodegenerative disorder typically characterised by cerebellar dysfunction, parkinsonism, pyramidal signs and dysautonomy. Cognitive impairement is usually limited to a moderate subcortical dysexecutive syndrom. We report the case of a 62-year-old woman suffering from MSA who progressively developed severe dementia. Neuropathological examination confirmed the diagnosis of definite MSA and also showed histopathological hallmarks of Alzheimer's disease. This association is extremely rare in the literature. Our observation confirmes that franc dementia in MSA should prompt a search for another associated cause and underlines the usefulness of neuropathological verifications in atypical clinical pictures.
Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/pathology , Multiple System Atrophy/complications , Multiple System Atrophy/pathology , Brain/pathology , Cerebellum/pathology , Cerebral Cortex/pathology , Fatal Outcome , Female , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Middle Aged , Plaque, Amyloid/pathologyABSTRACT
During the last two years, reports on laparoscopic procedures of the pancreas have been on increase. Laparoscopic resection of the pancreatic cauda is indicated, primarily, for benign cystic lesions of the cauda of the pancreas and for neuroendocrine tumors of the pancreas (mainly insulinomas). We have not recorded any report on the above procedure in the Czech literature. Therefore, in our case review, we have described laparoscopic distal resection of the pancreas with splenectomy for a pseudopapillary tumor of the pancreas.
Subject(s)
Laparoscopy , Pancreatectomy/methods , Adult , Female , Humans , Pancreatic Neoplasms/surgeryABSTRACT
Paraneoplastic cerebellar degeneration is a rare disorder caused likely by autoimmune mechanisms in malignant oncologic diseases, and the most common tumors are ovarian, breast, lung cancer, and m. Hodgkin. An immune reaction is supposed to be directed against identical antigens of cerebellum and tumor, and paraneoplastic antibodies called anti-Yo, anti-Hu, anti-Ri, or anti-Tr are often detected in blood and cerebrospinal fluid. The course of paraneoplastic cerebellar degeneration as a complication of ovarian cancer is described. The relationship between the malignancy and pathologic changes in cerebellum was confirmed by positive immunohistochemical and immunofluorescence reaction between a patient's anti-Yo-positive serum and her own Purkinje's and ovarian cancer cells.